CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab

J. J. Ifthikharuddin; L. A. Mieles; J. D. Rosenblatt; C. K. Ryan; D. M. Sahasrabudhe

doi:10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab

J. J. Ifthikharuddin, L. A. Mieles, J. D. Rosenblatt, C. K. Ryan, D. M. Sahasrabudhe

Research output: Contribution to journal › Article

33 Scopus citations

Abstract

B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

Original language	English (US)
Pages (from-to)	171-173
Number of pages	3
Journal	American Journal of Hematology
Volume	65
Issue number	2
DOIs	https://doi.org/10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z
State	Published - Oct 5 2000
Externally published	Yes

Fingerprint

Keywords

CD-20
Post-transplant lymphoproliferative disorder
PTLD
Rituximab

ASJC Scopus subject areas

Hematology

Cite this

Ifthikharuddin, J. J., Mieles, L. A., Rosenblatt, J. D., Ryan, C. K., & Sahasrabudhe, D. M. (2000). CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab. American Journal of Hematology, 65(2), 171-173. https://doi.org/10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

@article{3ce4836ab91940988905d6e69cbe853d,

title = "CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab",

abstract = "B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.",

keywords = "CD-20, Post-transplant lymphoproliferative disorder, PTLD, Rituximab",

author = "Ifthikharuddin, {J. J.} and Mieles, {L. A.} and Rosenblatt, {J. D.} and Ryan, {C. K.} and Sahasrabudhe, {D. M.}",

year = "2000",

month = oct

day = "5",

doi = "10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z",

language = "English (US)",

volume = "65",

pages = "171--173",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - CD-20 expression in post-transplant lymphoproliferative disorders

T2 - Treatment with rituximab

AU - Ifthikharuddin, J. J.

AU - Mieles, L. A.

AU - Rosenblatt, J. D.

AU - Ryan, C. K.

AU - Sahasrabudhe, D. M.

PY - 2000/10/5

Y1 - 2000/10/5

N2 - B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

AB - B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

KW - CD-20

KW - Post-transplant lymphoproliferative disorder

KW - PTLD

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0033828581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033828581&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

DO - 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

M3 - Article

C2 - 10996837

AN - SCOPUS:0033828581

VL - 65

SP - 171

EP - 173

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -

Access to Document

10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z